Summit Therapeutics Inc. (SMMT)
$
23.7
-0.72 (-3.04%)
Key metrics
Financial statements
Free cash flow per share
-0.2793
Market cap
18.1 Billion
Price to sales ratio
0
Debt to equity
0.0214
Current ratio
5.1262
Income quality
0.2773
Average inventory
0
ROE
-2.0863
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Summit Therapeutics Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing medicines aimed at treating infectious diseases in the United States and Latin America. The firm has a clinical program primarily dedicated to combating Clostridioides difficile infection (CDI), with ridinilazole as its lead product candidate. This orally administered small molecule antibiotic is currently in Phase III clinical trials for CDI treatment. In addition to ridinilazole, Summit Therapeutics offers SMT-738, targeting multidrug-resistant infections, particularly those caused by carbapenem-resistant Enterobacteriaceae, as well as the DDS-04 series designed for the potential treatment of Enterobacteriaceae-related infections. Despite its innovative advancements, the company reported a net loss of -$221,315,000.00 indicating challenges in its operations. The gross profit ratio stands at 0.00 showcasing the efficiency of its production and sales processes. Moreover, the EBITDA ratio of 0.00 highlights operational efficiency, even as the company faces selling, general, and administrative expenses of $60,527,000.00 reflecting its operational overhead costs. The company’s stock is traded under the symbol 'SMMT' in the market, providing investors with insight into its financial performance. The stock is affordable at $25.40 catering to budget-conscious investors who are looking for opportunities in the biopharmaceutical space. Additionally, the stock enjoys a high average trading volume of 3,735,739.00 which indicates strong liquidity and investor interest. With a mid-range market capitalization of $17,601,181,830.00 the company is regarded as a steady performer within its sector. As a key player in the Biotechnology industry, Summit Therapeutics contributes significantly to the overall market landscape, driving innovation and growth. Belonging to the Healthcare sector, it plays a crucial role in advancing solutions to pressing health challenges, continuing to pave the way for new treatments amid its ongoing clinical trials and research initiatives.
Is Summit Therapeutics Inc. (SMMT) a good investment?
Investing in Summit Therapeutics Inc. (SMMT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Summit Therapeutics Inc. (SMMT)'s stock forecast?
Analysts predict Summit Therapeutics Inc. stock to fluctuate between $11.76 (low) and $36.91 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Summit Therapeutics Inc.'s market capitalization?
As of 2025-08-29, Summit Therapeutics Inc.'s market cap is $17,601,181,830, based on 742,665,900 outstanding shares.
How does Summit Therapeutics Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Summit Therapeutics Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Summit Therapeutics Inc. (SMMT) stock?
To buy Summit Therapeutics Inc. (SMMT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SMMT. Place an order (Market, Limit, etc.).
What is the best time to invest in Summit Therapeutics Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Summit Therapeutics Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.31 | Growth: -68.69%.
Where can I find Summit Therapeutics Inc.'s investor relations reports?
Visit https://www.summittxinc.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Summit Therapeutics Inc.?
You can explore historical data from here
What is the all-time high and low for Summit Therapeutics Inc. stock?
All-time high: $36.91 (2025-04-24) | All-time low: $0.66 (2022-12-02).
What are the key trends affecting Summit Therapeutics Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.
prnewswire.com
LOS ANGELES , Aug. 12, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Summit Therapeutics Inc. ("Summit" or "the Company") (NASDAQ: SMMT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 17, 2022 and September 22, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before September 24, 2025.
businesswire.com
LOS ANGELES--(BUSINESS WIRE)---- $SMMT--SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law Firm.
businesswire.com
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the second quarter ended June 30, 2025. Operational & Corporate Updates Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with.
prnewswire.com
NEW YORK , July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
businesswire.com
LOS ANGELES--(BUSINESS WIRE)---- $SMMT--SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm.
prnewswire.com
NEW YORK , July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
fool.com
Is it worth it to buy a stock after it experiences significant market gains? The answer is, it depends.
fool.com
One day before the July Fourth holiday, the stock of clinical-stage biotech Summit Therapeutics (SMMT 8.18%) exploded like a powerful fireworks display. Shares of the cancer-focused company leaped by 8%, on a media report that a well-known peer was interested in a licensing deal.
globenewswire.com
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
See all news
